ChemoCentryx (CCXI) to Present Positive CCX168 Phase 2 Data at ASN Kidney Week 2016
Tweet Send to a Friend
ChemoCentryx, Inc., (Nasdaq: CCXI) announced that positive data from an ongoing Phase II proof-of-concept study of CCX168 for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
